Are There Benefits and Risks to Biosimilars from a Patient Perspective
Published on Aug 1, 2019in Rheumatic Diseases Clinics of North America3.527
· DOI :10.1016/j.rdc.2019.04.001
: Biosimilars are copies of biologic medications, which no longer are protected by patent, that are intended to be marketed at lower prices than their reference products to increase patient access to treatment. Because a biosimilar must have equivalent pharmacokinetic parameters and efficacy and comparable safety and immunogenicity with its reference product, the only significant difference between the two should be cost. Lower-priced biosimilars are intended to introduce market competition. The availability of biosimilars should yield savings for the health care system and improve treatment outcomes by expanding patient access to effective medications. However, patients should partake of these cost savings.